- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06686394
Studie Patritumab Deruxtecan s dalšími protirakovinnými látkami u účastníků s HER2 pozitivním karcinomem prsu, který se rozšířil a nelze jej chirurgicky odstranit (MK-1022-009)
HERTHENA-Breast-01: Fáze 1b/2, multicentrická, otevřená studie pro vyhledávání dávek k vyhodnocení bezpečnosti a protinádorové aktivity Patritumab Deruxtecan u účastníků s HER2 pozitivním neresekovatelným lokálně pokročilým karcinomem prsu nebo metastatickým karcinomem prsu
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:
- About the safety and how well people tolerate of patritumab deruxtecan
- How many people have the cancer respond (get smaller or go away) to treatment
Přehled studie
Postavení
Podmínky
Detailní popis
The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 2
- Fáze 1
Kontakty a umístění
Studijní kontakt
- Jméno: Toll Free Number
- Telefonní číslo: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studijní místa
-
-
-
Haifa, Izrael, 3109601
- Nábor
- Rambam Health Care Campus ( Site 0011)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 04-7776234
-
Petah Tikva, Izrael, 4941492
- Nábor
- Rabin Medical Center ( Site 0012)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +972-505533121
-
Ramat Gan, Izrael, 5265601
- Nábor
- Sheba Medical Center ( Site 0010)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 03-5304498
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japonsko, 467-8602
- Nábor
- Nagoya City University Hospital ( Site 0020)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +81-52-851-5511
-
-
-
-
-
Seoul, Jižní Korea, 03080
- Nábor
- Seoul National University Hospital ( Site 0030)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 82-2-2072-0850
-
Seoul, Jižní Korea, 05505
- Nábor
- Asan Medical Center ( Site 0031)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +82-2-1688-7575
-
-
-
-
Ontario
-
Kingston, Ontario, Kanada, K7L 2V7
- Nábor
- Kingston General Hospital ( Site 0061)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 6135336541
-
Toronto, Ontario, Kanada, M5G 2M9
- Nábor
- Princess Margaret Cancer Centre ( Site 0001)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 416-946-4501
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Nábor
- Jewish General Hospital ( Site 0003)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 514-340-8222
-
Montreal, Quebec, Kanada, H2X 3E4
- Nábor
- Centre Hospitalier de l'Université de Montréal ( Site 0004)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: (514)890-8000 x20737
-
-
-
-
Camden
-
London, Camden, Spojené království, NW1 2PG
- Nábor
- University College London Hospital ( Site 0041)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +442034472930
-
-
Glasgow City
-
Glasgow, Glasgow City, Spojené království, G12 0YN
- Nábor
- The Beatson West of Scotland Cancer Centre ( Site 0043)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +441413017000
-
-
London, City of
-
London, London, City of, Spojené království, EC1A 7BE
- Nábor
- St Bartholomew s Hospital ( Site 0040)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: +442073777000
-
-
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- Nábor
- University of Colorado Anschutz Medical Campus ( Site 0057)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 720-848-1030
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Nábor
- Dana-Farber Cancer Institute ( Site 0050)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 877-338-7425
-
-
New Jersey
-
New Brunswick, New Jersey, Spojené státy, 08901
- Nábor
- Rutgers Cancer Institute of New Jersey ( Site 0052)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 732-235-2465
-
-
South Carolina
-
Greenville, South Carolina, Spojené státy, 29605
- Nábor
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 864-455-3600
-
-
Virginia
-
Fairfax, Virginia, Spojené státy, 22031
- Nábor
- Inova Schar Cancer Institute ( Site 0051)
-
Kontakt:
- Study Coordinator
- Telefonní číslo: 571-472-4724
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
- Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention
Part 1 Arm 1:
- Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
- Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment
Part 1 Arm 2:
-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
Part 1 Arm 3:
-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.
Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Uncontrolled or significant cardiovascular disease
- Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
- Has clinically severe respiratory compromise
- Has any history of or evidence of any current leptomeningeal disease
- Has clinically significant corneal disease
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
- HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Part 1: Evidence of spinal cord compression or brain metastases
- Part 2: Evidence of spinal cord compression or brain/CNS metastases.
- Has an active infection requiring systemic therapy
- Concurrent active HBV and HCV infection
- Has had major surgical procedure (excluding placement of vascular access) less than 28 days
Part1: Arm 3 ONLY
- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Sekvenční přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Part 1: Patritumab deruxtecan plus trastuzumab
Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Ostatní jména:
Trastuzumab administered via IV infusion
Ostatní jména:
Trastuzumab biosimilar administered via IV infusion
Ostatní jména:
|
|
Experimentální: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Ostatní jména:
Trastuzumab administered via IV infusion
Ostatní jména:
Trastuzumab biosimilar administered via IV infusion
Ostatní jména:
Pertuzumab administered via IV infusion |
|
Experimentální: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib
Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Ostatní jména:
Trastuzumab administered via IV infusion
Ostatní jména:
Trastuzumab biosimilar administered via IV infusion
Ostatní jména:
Tucatinib administered as oral tablets |
|
Experimentální: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Ostatní jména:
Trastuzumab administered via IV infusion
Ostatní jména:
Trastuzumab biosimilar administered via IV infusion
Ostatní jména:
Pertuzumab administered via IV infusion |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Časové okno: Up to 21 days
|
DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
Časové okno: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Časové okno: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 12 months
|
|
Part 2: Objective Response Rate (ORR)
Časové okno: Up to approximately 36 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented. |
Up to approximately 36 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Časové okno: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Časové okno: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Časové okno: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Časové okno: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Časové okno: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Časové okno: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Časové okno: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Časové okno: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Časové okno: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 2: Duration of Response (DOR)
Časové okno: Up to approximately 36 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Progression Free Survival (PFS)
Časové okno: Up to approximately 36 months
|
PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants with One or More AEs
Časové okno: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Časové okno: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 12 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Ředitel studie: Medical Director, Merck Sharp & Dohme LLC
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Novotvary podle místa
- Novotvary
- Kožní choroby
- Nemoci prsu
- Onemocnění kůže a pojivové tkáně
- Novotvary prsu
- Aminokyseliny, peptidy a proteiny
- Proteiny
- Protilátky, monoklonální, humanizované
- Protilátky, monoklonální
- Protilátky
- Imunoglobuliny
- Imunoproteiny
- Krevní proteiny
- Sérové globuliny
- Globuliny
- Trastuzumab
- pertuzumab
- Tucatinib
- Patritumab deruxtecan
- Ogivri
- OnTruzant
Další identifikační čísla studie
- 1022-009
- MK-1022-009 (Jiný identifikátor: MSD)
- jRCT2041250022 (Identifikátor registru: Japan Registry of Clinical Trials (jRCT))
- 2026-528266-19 (Identifikátor registru: EU CT)
- U1111-1346-4321 (Identifikátor registru: UTN)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .